Omeros (OMER) Receivables (2010 - 2026)
Omeros recorded quarterly Receivables of $12.1 million in Q1 2026, up 3.92% quarter-over-quarter from $11.7 million in Q4 2025, and up 42.23% year-over-year from $8.5 million in Q1 2025.
Omeros' Receivables history runs 17 years deep, the most recent figure standing at $12.1 million for Q1 2026.
- In Q1 2026, Receivables rose 42.23% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $12.1 million (up 42.23% YoY), while the FY2025 annual figure was $11.7 million, up 36.65% from the prior year.
- Receivables came in at $12.1 million for Q1 2026 at Omeros, up from $11.7 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $226.2 million in Q4 2022 to a low of $7.3 million in Q2 2025.
- A 5-year average of $24.1 million and a median of $11.7 million in 2025 frame the typical range for Receivables.
- Across the five-year window, Receivables soared 8324.1% in 2022 and tumbled 95.81% in 2023, its largest moves.
- Omeros' Receivables stood at $226.2 million in 2022, then sank by 95.81% to $9.5 million in 2023, then slipped by 9.82% to $8.5 million in 2024, then jumped by 36.65% to $11.7 million in 2025, then grew by 3.92% to $12.1 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $12.1 million, $11.7 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 12.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.12 Mn |
| Dec 31, 2025 | 11.67 Mn |
| Sep 30, 2025 | 7.77 Mn |
| Jun 30, 2025 | 7.34 Mn |
| Mar 31, 2025 | 8.52 Mn |
| Dec 31, 2024 | 8.54 Mn |
| Sep 30, 2024 | 12.49 Mn |
| Jun 30, 2024 | 14.89 Mn |
| Mar 31, 2024 | 8.30 Mn |
| Dec 31, 2023 | 9.47 Mn |
| Sep 30, 2023 | 13.54 Mn |
| Jun 30, 2023 | 11.32 Mn |
| Mar 31, 2023 | 10.30 Mn |
| Dec 31, 2022 | 226.19 Mn |
| Sep 30, 2022 | 14.64 Mn |
| Jun 30, 2022 | 15.31 Mn |
| Mar 31, 2022 | 16.66 Mn |
| Dec 31, 2021 | 2.69 Mn |
| Sep 30, 2021 | 33.90 Mn |
| Jun 30, 2021 | 32.26 Mn |
| Mar 31, 2021 | 24.83 Mn |
| Dec 31, 2020 | 3.84 Mn |
| Sep 30, 2020 | 37.54 Mn |
| Jun 30, 2020 | 15.87 Mn |
| Mar 31, 2020 | 24.12 Mn |
| Dec 31, 2019 | 35.19 Mn |
| Sep 30, 2019 | 30.05 Mn |
| Jun 30, 2019 | 28.52 Mn |
| Mar 31, 2019 | 24.86 Mn |
| Dec 31, 2018 | 22.98 Mn |
| Sep 30, 2018 | 2.43 Mn |
| Jun 30, 2018 | 1.56 Mn |
| Mar 31, 2018 | 315,000.00 |
| Dec 31, 2017 | 17.21 Mn |
| Sep 30, 2017 | 24.57 Mn |
| Jun 30, 2017 | 19.08 Mn |
| Mar 31, 2017 | 13.48 Mn |
| Dec 31, 2016 | 12.14 Mn |
| Sep 30, 2016 | 10.46 Mn |
| Jun 30, 2016 | 8.81 Mn |
| Mar 31, 2016 | 6.65 Mn |
| Dec 31, 2015 | 6.65 Mn |
| Sep 30, 2015 | 2.51 Mn |
| Jun 30, 2015 | 3.07 Mn |
| Mar 31, 2015 | 538,000.00 |
| Dec 31, 2014 | 716,000.00 |
| Sep 30, 2014 | 381,000.00 |
| Jun 30, 2014 | 252,000.00 |
| Mar 31, 2014 | 488,000.00 |
| Dec 31, 2013 | 450,000.00 |
| Sep 30, 2013 | 881,000.00 |
| Jun 30, 2013 | 715,000.00 |
| Mar 31, 2013 | 2.00 Mn |
| Dec 31, 2012 | 3.42 Mn |
| Sep 30, 2012 | 467,000.00 |
| Jun 30, 2012 | 767,000.00 |
| Mar 31, 2012 | 1.64 Mn |
| Dec 31, 2011 | 890,000.00 |
| Sep 30, 2011 | 776,000.00 |
| Jun 30, 2011 | 2.46 Mn |
| Dec 31, 2010 | 1.48 Mn |